array(3) { ["company_details"]=> array(13) { ["name"]=> string(29) "Regeneron Pharmaceuticals Inc" ["slug"]=> string(38) "c469a-us-regeneron-pharmaceuticals-inc" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77" ["description"]=> string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in. Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. " ["address_street"]=> string(25) "777 Old Saw Mill River Rd" ["address_place"]=> string(9) "Tarrytown" ["address_region"]=> string(8) "New York" ["founding_date"]=> string(10) "1988-02-08" ["website_domain"]=> string(13) "regeneron.com" ["website_url"]=> string(25) "https://www.regeneron.com" ["industry_codes"]=> array(1) { [0]=> string(27) "Pharmaceutical Preparations" } ["employee_count"]=> int(10368) ["article_count"]=> int(2748) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(64) "Regeneron 'Safe Harbor' Argument Rejected in Covid Cocktail Suit" ["snippet_en"]=> string(253) "Regeneron Pharmaceuticals Inc.’s infringement of a California biotechnology company’s patent for technology used to develop its Covid-19 “antibody cocktail” isn’t immunized by the US Patent Act’s safe harbor provision, a federal judge ruled." ["url"]=> string(99) "https://news.bloomberglaw.com/ip-law/regeneron-safe-harbor-argument-rejected-in-covid-cocktail-suit" ["image_url"]=> NULL ["source"]=> string(16) "bloomberglaw.com" ["publication_date"]=> string(10) "2024-10-05" ["categories"]=> array(4) { [0]=> string(8) "Epidemic" [1]=> string(10) "Litigation" [2]=> string(21) "Intellectual Property" [3]=> string(5) "Legal" } } [1]=> array(7) { ["title_en"]=> string(66) "Regeneron Pharmaceuticals: Patent for Abnormal Karyotype Detection" ["snippet_en"]=> string(168) "Discover Regeneron Pharmaceuticals' groundbreaking patent for detecting abnormal karyotypes through advanced sequencing methods, enhancing genomic analysis reliability." ["url"]=> string(152) "https://www.pharmaceutical-technology.com/data-insights/regeneron-pharmaceuticals-gets-grant-for-detecting-abnormal-karyotypes-using-sequencing-methods/" ["image_url"]=> NULL ["source"]=> string(29) "pharmaceutical-technology.com" ["publication_date"]=> string(10) "2024-09-25" ["categories"]=> array(1) { [0]=> string(21) "Intellectual Property" } } [2]=> array(7) { ["title_en"]=> string(55) "Amgen Gets Legal Win in Eylea Patent Row With Regeneron" ["snippet_en"]=> string(169) "Regeneron’s lawsuit, filed earlier this year, alleged more than 30 counts of patent infringement against Amgen and its biosimilar to the blockbuster eye therapy Eylea." ["url"]=> string(87) "https://www.biospace.com/policy/amgen-gets-legal-win-in-eylea-patent-row-with-regeneron" ["image_url"]=> string(78) "https://images.businessradar.com/articles/6cfe9de7-cf05-400c-871a-c91302a00315" ["source"]=> string(12) "biospace.com" ["publication_date"]=> string(10) "2024-09-24" ["categories"]=> array(2) { [0]=> string(21) "Intellectual Property" [1]=> string(5) "Legal" } } [3]=> array(7) { ["title_en"]=> string(64) "Regeneron Appeals After Judge Declines to Block Amgen Biosimilar" ["snippet_en"]=> string(194) "Regeneron Pharmaceuticals Inc. quickly appealed a judge’s order declining to block Amgen Inc.'s biosimilar version of its blockbuster eye drug Eylea while a patent-infringement suit continues." ["url"]=> string(124) "https://news.bloomberglaw.com/product-liability-and-toxics-law/regeneron-fails-to-block-amgens-eylea-biosimilar-files-appeal" ["image_url"]=> string(78) "https://images.businessradar.com/articles/49442da2-30a0-40a0-9b78-9bb6c8faf4a2" ["source"]=> string(16) "bloomberglaw.com" ["publication_date"]=> string(10) "2024-09-24" ["categories"]=> array(3) { [0]=> string(8) "Verdicts" [1]=> string(21) "Intellectual Property" [2]=> string(5) "Legal" } } [4]=> array(7) { ["title_en"]=> string(38) "Legal Lens on the Unified Patent Court" ["snippet_en"]=> string(190) "The Unified Patent Court (UPC) is revolutionizing the way patents are enforced in Europe, and McDermott’s intellectual property team is here to help you navigate this dynamic landscape...." ["url"]=> string(81) "https://www.jdsupra.com/legalnews/legal-lens-on-the-unified-patent-court-9286045/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/bf0f869d-23c7-46f1-80e7-1401254eded4" ["source"]=> string(11) "jdsupra.com" ["publication_date"]=> string(10) "2024-08-29" ["categories"]=> array(4) { [0]=> string(8) "Verdicts" [1]=> string(21) "Competitive Behaviour" [2]=> string(21) "Intellectual Property" [3]=> string(5) "Legal" } } [5]=> array(7) { ["title_en"]=> string(104) "Do intellectual property rights hinder or promote vaccine development? Doctors Without Borders tells you" ["snippet_en"]=> string(106) "Myth: Intellectual property rights enable breakthroughs in the development of COVID-19 drugs and vaccines." ["url"]=> string(38) "https://www.coolloud.org.tw/node/95865" ["image_url"]=> string(78) "https://images.businessradar.com/articles/6271f580-5986-4c05-a5b8-32b6ce02699c" ["source"]=> string(15) "coolloud.org.tw" ["publication_date"]=> string(10) "2024-03-04" ["categories"]=> array(6) { [0]=> string(14) "Product Launch" [1]=> string(8) "Epidemic" [2]=> string(11) "Competition" [3]=> string(21) "Competitive Behaviour" [4]=> string(21) "Intellectual Property" [5]=> string(24) "Access and affordability" } } [6]=> array(7) { ["title_en"]=> string(46) "Amgen defends patent for cholesterol treatment" ["snippet_en"]=> string(238) "The EPO Opposition Division in The Hague upheld Amgen’s patent for the biotechnologically produced active ingredient evolocumab (EP 2 215 124). The patent was granted on February 24, 2016, and Sanofi filed an opposition on the same day." ["url"]=> string(81) "https://www.juve-patent.com/cases/amgen-defends-patent-for-cholesterol-treatment/" ["image_url"]=> NULL ["source"]=> string(15) "juve-patent.com" ["publication_date"]=> string(10) "2024-01-19" ["categories"]=> array(4) { [0]=> string(13) "Collaboration" [1]=> string(10) "Litigation" [2]=> string(21) "Intellectual Property" [3]=> string(5) "Legal" } } [7]=> array(7) { ["title_en"]=> string(55) "Regeneron patent victory 'a significant positive' - UBS" ["snippet_en"]=> string(55) "Regeneron patent victory 'a significant positive' - UBS" ["url"]=> string(115) "https://www.investing.com/news/stock-market-news/regeneron-patent-victory-a-significant-positive--ubs-432SI-3264471" ["image_url"]=> NULL ["source"]=> string(13) "investing.com" ["publication_date"]=> string(10) "2023-12-28" ["categories"]=> array(2) { [0]=> string(21) "Intellectual Property" [1]=> string(27) "Business Model & Innovation" } } [8]=> array(7) { ["title_en"]=> string(57) "Regeneron surges after patent case ruling against Viatris" ["snippet_en"]=> string(57) "Regeneron surges after patent case ruling against Viatris" ["url"]=> string(120) "https://www.investing.com/news/stock-market-news/regeneron-surges-after-patent-case-ruling-against-viatris-432SI-3264127" ["image_url"]=> NULL ["source"]=> string(13) "investing.com" ["publication_date"]=> string(10) "2023-12-27" ["categories"]=> array(5) { [0]=> string(16) "Case Settlements" [1]=> string(8) "Verdicts" [2]=> string(21) "Intellectual Property" [3]=> string(27) "Business Model & Innovation" [4]=> string(5) "Legal" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(263) } [1]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(201) } [2]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(196) } [3]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(129) } [4]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(116) } [5]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(116) } [6]=> array(2) { ["name"]=> string(5) "Event" ["count"]=> int(93) } [7]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(79) } [8]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(67) } [9]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(66) } [10]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(61) } [11]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(59) } [12]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(57) } [13]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(56) } [14]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(53) } [15]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(43) } [16]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(40) } [17]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(38) } [18]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(37) } [19]=> array(2) { ["name"]=> string(8) "Verdicts" ["count"]=> int(37) } [20]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(37) } [21]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(35) } [22]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(33) } [23]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(32) } [24]=> array(2) { ["name"]=> string(13) "Data Security" ["count"]=> int(31) } [25]=> array(2) { ["name"]=> string(27) "Business Model & Innovation" ["count"]=> int(28) } [26]=> array(2) { ["name"]=> string(14) "Product Review" ["count"]=> int(28) } [27]=> array(2) { ["name"]=> string(24) "Access and affordability" ["count"]=> int(25) } [28]=> array(2) { ["name"]=> string(11) "Sponsorship" ["count"]=> int(21) } [29]=> array(2) { ["name"]=> string(21) "Intellectual Property" ["count"]=> int(20) } } } c469a-us-regeneron-pharmaceuticals-inc